A Phase 2 interventional study of VX-548 and Placebo in Painful Lumbosacral Radiculopathy, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 54 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-10-01.
Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies in Radiculopathy with a site in United States — 29 open to participants now, 37 under way, 2 of them phase 3. Radiculopathy · United States.
Among the 126 studies in Radiculopathy with a site in United States, this one is the 18th largest by enrollment of the 106 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 in phase 2, and was the 111th registered.
484 studies on the registry are indexed under Radiculopathy; 144 are open to participants now.
Browse Radiculopathy studies →29 of the 126 studies in Radiculopathy with a site in United States are open now. Recruiting first, the newest first:
Liberty University · Sites in United States
Ages 18+
Vertanical GmbH · Sites in United States
Ages 18+
Georgetown University · Sites in United States
Ages 18+
University of California, San Francisco · Sites in United States
Ages 18+
Northwestern University · Sites in United States, Thailand, Ukraine
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 79 Radiculopathy studies recruiting now, 23 (29%) set no upper age limit and 48 (61%) stop at 75 or younger; 3 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 17 · Phase 3 19 · Phase 4 9
First in 2001; this study’s year is marked. 5 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 60 across 374 interventional studies indexed under Radiculopathy.
Median enrollment 78 across the 106 interventional studies, 54 across the 20 observational. Of the 73 that completed or were terminated, 29 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 126 have an industry lead sponsor. The 10 most frequent:
Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.
Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.
Vertex Pharmaceuticals Incorporated has 1 study filed under Radiculopathy — fewer than ten, so there is no comparison to draw.
12 of the studies in Radiculopathy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07125027National University of Natural MedicineA Multicomponent Intervention for Patients With Lumbosacral Radiculopathy: Move-MORE | 2026-11 |
| NCT03023696The Cleveland ClinicCan Prophylactic Foraminotomy Prevent C5 Palsy | 2026-12 |
| NCT05593237University of California, San FranciscoTranscranial Magnetic Stimulation for Chronic Neuropathic Pain | 2026-12-30 |
| NCT07397117University of California, San FranciscoComparing Ultrasound-Guided Transgluteal Nerve Block to Standard Care | 2026-12-31 |
| NCT04982965University of California, San DiegoBrain Mechanisms Supporting Cannabis-induced Pain Relief | 2027-01-15 |
Add all 12 to your calendar (.ics) → With an account.
Among the 126 studies in Radiculopathy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive VX-548 up to 12 weeks.
Drug: VX-548
Participants will receive placebo matched to VX-548 up to 12 weeks.
Drug: Placebo
Tablets for oral administration.
Also known as: Suzetrigine
Tablets for oral administration.
Change From Baseline in the Weekly Average of Daily leg Pain Intensity on a Numeric Pain Rating Scale (NPRS)
Time frame: Baseline, Week 12
Change From Baseline in the Weekly Average of the Daily Sleep Interference Scale (DSIS)
Time frame: Baseline, Week 12
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From Day 1 up to Week 14
Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Ran from Dec 2023 to primary completion in Oct 2024, 9 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Suzetrigine
Vertex Pharmaceuticals Incorporated →